US Pharma MarketingAnother Paragon offshoot chooses reverse merger, this time for migraine drugs
Paragon Therapeutics is taking eighth spinout Mentari Therapeutics public via a reverse merger with InMed Pharmaceuticals, paired with a $290 million private p…Paragon Therapeutics is taking eighth spinout Mentari Therapeutics public via a reverse merger with InMed Pharmaceuticals, paired with a $290 million private placement to advance PACAP-targeting migraine drugs. Topic Hubs AI drug discovery: News, analysis and interviews Antibody-drug conjugates: The next wave of targeted cancer drugs Biopharma M&A and dealmaking: Who’s buying and why Biopharma people moves: CEO changes, executive hires, board positions Biotech IPOs: Tracking the market for new public offerings Biotech venture funding: Who’s raising and…
They say stick to what you know. And Paragon Therapeutics knows how to do reverse mergers.
The hub-and-spoke biologics company is moving its migraine drug offshoot, Mentari Therapeutics, onto the public markets through a takeover ...
Source: Endpoints News